Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 7, 2026; 32(25): 118842
Published online Jul 7, 2026. doi: 10.3748/wjg.118842
Published online Jul 7, 2026. doi: 10.3748/wjg.118842
Figure 5 Immunohistochemical staining of additional gastric intestinal metaplasia patients.
Positive staining for CES2, CRIP1, DHRS11, EPCAM, FOLH1, NPC1 L1, S100A10, and TMEM176B is observed in brown color. N group: Non-progression group; P group: Progression group; IM: Intestinal metaplasia.
- Citation: He S, Guo XF, Wang Y, Bai JQ, Wang JP, Shi JH, Shi YY, Yuan J, Wei W, Yang Y, Shi XH, Feng Y, Ding X, Gao W, Lu D, Zhou WX, Zhang P. FOLH1 as a novel biomarker for risk stratification in gastric intestinal metaplasia. World J Gastroenterol 2026; 32(25): 118842
- URL: https://www.wjgnet.com/1007-9327/full/v32/i25/118842.htm
- DOI: https://dx.doi.org/10.3748/wjg.118842